Phreesia, Inc.

NYSE:PHR

Medical - Healthcare Information Services

Healthcare
$12.26 +0.80%

+$0.08 today

Market cap
$760.99M
Beta
0.88
P/E (TTM)
62.6
EPS (TTM)
$0.15
52W Low $7.77High $32.76

Volume 0.86M

Average 1.97M

PHR Cost of Revenue

Direct costs of producing the goods and services sold, such as materials, manufacturing, and service delivery.

Phreesia, Inc.NYSE: PHR

Cost of Revenue · Q1 FY2027 · quarter ended Apr 2026

Cost of revenue growth accelerates

Q1 FY2027 cost of revenue of $53.4M rose 40.3% year over year, ahead of the +21.9% change in trailing-twelve-month cost of revenue. Sequentially, it rose 32.2% from the prior quarter. Over 3 fiscal years it compounded at +12.1% a year.

Context

  • Cost of revenue amounted to 32.1% of revenue in FY2026, unchanged from a year earlier.
  • Cost of revenue increased in 3 of the last 3 fiscal years.
  • FY2026 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +40.3% holds above the trailing-twelve-month pace of +21.9%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterApr 2026
$53.4M+32.2% QoQ
Last fiscal yearJan 2026
$154.12M+14.2% YoY
LTMApr 2026
$169.46M+21.9% YoY
Cost of Revenue past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+40.3%——
1 year+14.2%——
3-year CAGR+12.1%——
5-year CAGR——
10-year CAGR——

Cost of Revenue history

USD · from the income statement

Latest · FY2026
154.12M USD
Year-over-year change
+14.2%
4-year CAGR
+17.3%

Cost of Revenue vs competitors

How PHR compares with its peers on the latest reported figures

  • PHR's LTM Apr 2026 cost of revenue of $169.46M is the 4th highest of the 11 companies compared; the peer median is $108.79M.
  • Its year-over-year change of +21.9% is the 5th highest of 11, against a peer median of +16.3%.
  • Cost of revenue amounts to 34.2% of revenue for PHR, versus a peer median of 35.2%.
PHR Competitors Peer median
Cost of Revenue for PHR and competitors
Company Period LTM YoY 3-year CAGR% of revenue
TDOCTeladoc Health, Inc.LTM Mar 2026$864.58M +14.7%+1.2%34.4%
OMCLOmnicell, Inc.LTM Mar 2026$692.19M +7.4%-1.4%56.5%
NEOGNeogen CorporationLTM Aug 2026$465.01M -11.0%+3.5%52.6%
PHRPhreesia, Inc.LTM Apr 2026$169.46M +21.9%+12.1%34.2%
NVCRNovoCure LimitedLTM Mar 2026$167.29M +17.8%+13.3%24.8%
SDGRSchrödinger, Inc.LTM Sep 2026$111.68M +3.9%+12.3%41.5%
GDRXGoodRx Holdings, Inc.LTM Mar 2026$105.91M +115.7%-4.0%13.4%
OMDAOmada HealthLTM Mar 2026$95.69M +31.6%+24.4%33.8%
ESTAEstablishment Labs Holdings Inc.LTM Sep 2026$78.74M +31.9%+5.5%29.8%
KMTSKestra Medical Technologies, Ltd.LTM Jan 2026$42.91M +23.8%—51.2%
BLFSBioLife Solutions, Inc.LTM Mar 2026$36.03M +2.6%+5.1%36.1%
Peer median (excluding PHR) $108.79M+16.3%+5.1%35.2%

Competitors are the stored peer set for PHR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2022
Jan 2022
FY2023
Jan 2023
FY2024
Jan 2024
FY2025
Jan 2025
FY2026
Jan 2026
Revenue213.23M280.91M356.3M419.81M480.59M
Cost of Revenue81.39M109.27M124.01M134.93M154.12M
Gross Profit131.85M171.64M232.29M284.88M326.47M
Gross Margin61.8%61.1%65.2%67.9%67.9%
Research & Development52.27M91.24M112.35M117.36M121.48M
Selling, General & Admin175.1M231.65M226.93M197.73M180.15M
Operating Expenses248.66M348.2M368.77M342.98M333.08M
Depreciation & Amortization24.52M28.77M30.54M27.89M31.45M
EBITDA(92.3M)(145.48M)(102.95M)(25.58M)29.47M
EBITDA Margin-43.3%-51.8%-28.9%-6.1%6.1%
Operating Income(116.82M)(176.55M)(136.48M)(58.1M)(6.61M)
Operating Margin-54.8%-62.9%-38.3%-13.8%-1.4%
Interest Income79K2.48M4.07M2.68M2.17M
Interest Expense1.16M1.41M1.85M2.35M6.95M
Other Income / Expenses(1.16M)889K1.14M2.29M(2.33M)
Income Before Tax(117.98M)(175.66M)(135.34M)(55.81M)(8.94M)
Pre-Tax Margin-55.3%-62.5%-38.0%-13.3%-1.9%
Income Tax Expense182K483K1.54M2.72M(11.25M)
Net Income(118.16M)(176.15M)(136.89M)(58.53M)2.31M
Net Margin-55.4%-62.7%-38.4%-13.9%0.5%
EPS (Basic)(2.37)(3.36)(2.51)(1.02)0.04
EPS (Diluted)(2.37)(3.36)(2.51)(1.02)0.04
Weighted Avg Shares49.89M52.44M54.56M57.59M59.74M
Weighted Avg Shares (Diluted)49.89M52.44M54.56M57.59M61.49M

Phreesia, Inc.

NYSE:PHR

Intrinsic Alpha fair value

Locked

Current Price

$12.26

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.